To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
About This Bill
Floor Vote
Latest Action · March 1, 2023
Placed on Senate Legislative Calendar under General Orders. Calendar No. 20.